APLT · Applied Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00M | $0 | $0 | - | $122.0K | $144.0K | $190.0K | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.60M | $9.92M | $7.84M | - | $14.83M | $10.00M | $12.22M | - | $10.79M | $11.88M |
| SG&A | $8.16M | $13.18M | $17.69M | - | $15.04M | $10.58M | $9.07M | - | $4.71M | $5.29M |
| Total Operating Expenses | $17.76M | $23.10M | $25.52M | - | $29.86M | $20.58M | $21.28M | - | $15.49M | $17.18M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($16.76M) | ($23.10M) | ($25.52M) | - | ($29.74M) | ($20.44M) | ($21.09M) | - | ($15.49M) | ($17.18M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($18.99M) | ($21.33M) | ($21.82M) | - | ($68.59M) | $2.90M | ($83.94M) | - | ($42.37M) | ($29.58M) |
| EPS - Basic | ($0.13) | ($0.15) | ($0.15) | - | ($0.48) | $0.02 | ($0.67) | - | ($0.47) | ($0.37) |
| EPS - Diluted | ($0.13) | ($0.15) | ($0.15) | - | ($0.48) | ($0.13) | ($0.67) | - | ($0.47) | ($0.37) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.95M | $30.42M | $50.76M | $79.40M | $98.87M | $122.20M | $146.48M | $49.90M | $37.46M | $35.62M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.80M | $4.86M | $4.87M | $4.43M | $2.84M | $2.68M | $4.02M | $1.74M | $6.00M | $4.69M |
| Current Assets | $31.65M | $34.51M | $53.97M | $83.65M | $104.60M | $127.57M | $150.91M | $54.39M | $44.49M | $42.82M |
| Total Assets | $34.37M | $37.34M | $56.91M | $86.69M | $106.57M | $127.78M | $151.23M | $54.83M | $45.20M | $43.65M |
| Current Liabilities | $32.90M | $17.75M | $17.96M | $27.30M | $98.97M | $55.36M | $83.91M | $71.18M | $55.50M | $47.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $34.94M | $19.90M | $20.24M | $29.68M | $100.67M | $55.39M | $83.94M | $71.98M | $56.24M | $47.98M |
| Stockholders' Equity | ($561.0K) | $17.44M | $36.67M | $57.01M | $5.89M | $72.39M | $67.29M | ($17.15M) | ($11.04M) | ($4.33M) |
| Retained Earnings | ($636.36M) | ($617.37M) | ($596.03M) | ($574.21M) | ($618.22M) | ($549.63M) | ($552.52M) | ($468.59M) | ($430.91M) | ($388.54M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($28.64M) | - | - | - | ($18.91M) | - | - | - |
| Investing Cash Flow | - | - | $0 | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $115.50M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1675.8% | - | - | - | -24379.5% | -14194.4% | -11101.6% | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -1899.0% | - | - | - | -56222.1% | 2012.5% | -44177.9% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 960.1% | - | - | - | 12154.1% | 6947.2% | 6430.0% | - | - | - |
| SG&A / Revenue | 815.7% | - | - | - | 12325.4% | 7347.2% | 4771.6% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -55.2% | -57.1% | -38.4% | - | -64.4% | 2.3% | -55.5% | - | -93.7% | -67.8% |
| Return on equity | 3385.0% | -122.3% | -59.5% | - | -1164.1% | 4.0% | -124.7% | - | 383.6% | 682.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.96 | 1.94 | 3.00 | 3.06 | 1.06 | 2.30 | 1.80 | 0.76 | 0.80 | 0.91 |
| Quick ratio | 0.96 | 1.94 | 3.00 | 3.06 | 1.06 | 2.30 | 1.80 | 0.76 | 0.80 | 0.91 |
| Cash ratio | 0.36 | 1.71 | 2.83 | 2.91 | 1.00 | 2.21 | 1.75 | 0.70 | 0.67 | 0.75 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -61.27 | 2.14 | 1.55 | 1.52 | 18.09 | 1.77 | 2.25 | -3.20 | -4.09 | -10.07 |
| Liabilities / Assets | 1.02 | 0.53 | 0.36 | 0.34 | 0.94 | 0.43 | 0.56 | 1.31 | 1.24 | 1.10 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 719.7% | -100.0% | -100.0% | - | - | - | -98.2% | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 43.7% | -13.0% | -21.0% | - | -92.0% | -19.0% | -94.3% | - | 19.9% | 20.2% |
| Net income growth (YoY) | 72.3% | - | 74.0% | - | -61.9% | - | -728.0% | - | -121.8% | -14.4% |
| EPS growth (YoY) | 72.9% | -15.4% | 77.6% | - | -2.1% | 64.9% | -272.2% | - | -17.5% | 61.5% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -75.9% | -45.5% | - | - | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$455.0K totalResearch And Development Services$455.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Applied Therapeutics Inc. against the 5 most active filers in the same SIC group.